Background: The change in the demographics and the presence of multiple risk factors and co-morbidities in UK patients starting dialysis may lead to poor survival on dialysis. Many of these risk factors are present in the pre-dialysis period allowing a potential window of opportunity to intervene with risk modification measures. Aim: To examine various potential factors that may predict early and overall mortality. Design and Methods: We carried out an observational prospective study of a cohort of incident patients starting dialysis in a UK centre. Univariate analysis of factors and co-morbidities potentially affecting survival on dialysis were analysed to potential predictors. Factors affecting 1 year mortality were analysed using the t-test, the MannWhitney U-test or the chi-square test as appropriate. Mortality over the 5-year follow-up period was analysed using the Kaplan-Meier method. Results: Ninety-four patients [predominantly Caucasian (98%)], of mean age 63 years (15.6) (56% > 65 years) with a slight male preponderance were studied. Vascular disease (39%) and sepsis
Introduction
Year on year the number of patients starting renal replacement therapy (RRT) has risen in the UK. This is mainly attributed to an increasing number of older patients and also those with co-morbid illnesses commencing RRT. 1 This change in demographics combined with the presence of multiple co-morbidities results in potentially poorer survival on dialysis. Multiple risk factors that predict mortality in this population (many cardiovascular in nature) have been identified. [2] [3] [4] [5] [6] It is also well recognized that these various risk factors for mortality in dialysis patients are present in the pre-dialysis stage. This, therefore, presents a valuable opportunity for potential intervention of those classical modifiable risk factors such as smoking, hypertension and diabetes and perhaps the renal-related factors including changes in renal bone biochemistry.
There is a complex interplay between the presence of various risk factors and the presence of co-morbid conditions at the commencement of dialysis. However, there are few studies in the current literature that comprehensively analyse the impact of these risk factors in relation to the multiple co-morbid conditions during the pre-dialysis stage on patient mortality after commencing dialysis therapy (both peritoneal and haemodialysis).
In this current study, we have sought to analyse multiple risk factors and co-morbid conditions present in patients starting renal replacement therapy in the East Yorkshire Region during a single year and the impact of these factors on mortality when followed up prospectively for 5 years.
Methods
We performed an observational prospective study of a cohort of 94 incident patients starting dialysis in a single centre in the UK; we analysed various potential factors that might predict early mortality (within 1 year of commencing dialysis) and mortality over 5 years. All adult patients who started renal replacement therapy (haemodialysis or peritoneal dialysis) in 2002 were included in the analysis. Patients dialysing for <90 days were excluded from the study. Patients were followed up for a total period of 5 years. Baseline characteristics of the study population are described. All-cause mortality was defined as the main outcome measure while mortality within the first year after commencing dialysis was defined as the secondary outcome measure. Potential factors that affected the mortality of the study population, including age at the time of dialysis, gender, smoking status (non-smokers, ex-smoker and current smoker), presence of diabetes mellitus, presence of left ventricular hypertrophy (LVH) diagnosed by ECG criteria and/or echocardiography, planning for the first dialysis with permanent access, type of dialysis (haemodialysis and peritoneal dialysis), time interval from referral to renal replacement therapy, referral eGFR, eGFR at the first dialysis, haemoglobin, serum albumin, cholesterol, triglycerides and calcium phosphate product were all included in the analysis. eGFR was measured by the four-variable MDRD (Modification of Diet in Renal Disease) equation. The presence of co-morbid conditions at the initiation of RRT, including ischaemic heart disease, cerebrovascular disease, peripheral vascular disease, chronic obstructive airway disease and non-dermatological malignancy, was also analysed to study their impact on overall mortality. The modifiable pre-dialysis factors such as serum albumin, haemoglobin, cholesterol, triglycerides and calcium phosphate product were measured at the commencement of renal replacement therapy. For haemoglobin as a pre-dialysis risk factor, patients were stratified into two groups based on haemoglobin at the start of dialysis (<11 g/dl and >11 g/dl). Similarly patients were stratified into three groups based on the time interval between renal referral and start of dialysis (0/12 months i.e. crash-landers, 0/12-12/12 months and >12/12 months).
All statistical analyses were carried out using SPSS for windows-version 17. All continuous variables were expressed either as means and standard deviation (SD) or medians and inter quartile range for variables that are not normally distributed. All categorical variables were described in terms of percentage of total study population. Early mortality was studied using either the Student t-test or the MannWhitney U-test for the continuous variables depending on the normality of the distribution and the chi-square test for the categorical variables. Analysis of the mortality over the follow-up period of 5 years was by the Kaplan-Meier method. A P-value of <0.05 was considered statistically significant.
Results
A total of 94 patients [predominantly Caucasian (98%, n = 92/94)] of mean age 63 years (15.6) (56% aged > 65 years) with a slight male preponderance were included in the analysis. Baseline characteristics of the study population are described in Table 1 . The median follow-up was 4.5 years [mean 4.7 years (0.6)]. Haemodialysis was the preferred chosen option by patients for RRT (n = 74; the 20 remaining patients chose peritoneal dialysis). Approximately half of the first dialysis sessions were planned with permanent access (fistula or peritoneal dialysis catheter). A significant proportion of the population (51%) had left ventricular hypertrophy (LVH), confirmed by ECG and/or echocardiogram, at the commencement of dialysis. During the study period, 24% (23/94) of patients were transplanted and have, therefore, been censored in the survival analysis. Of the patients starting dialysis therapy, 41% (39/94) died during the study period (primary end-point). Table 2 summarizes the mortality data. A significant proportion of the mortality occurred in the first year (56%) and either vascular disease or infection accounted for the majority of them.
Analysis of factors affecting early mortality (Table 3) showed that patients who died in the first year had lower eGFR and haemoglobin values. This group of patients were also older with higher calcium phosphate products (4.4 vs. 5.2 mmol 2 /l 2 ; P = 0.004) with more vascular disease at commencement of dialysis.
Patients with vascular disease, diabetes mellitus and in the highest quartile of the calcium phosphate product had significantly worse mean survival periods on dialysis (Table 4 , factors associated with overall mortality). From Kaplan-Meier survival curves, it was noted that patients with vascular disease had a 5-year survival of 35% as opposed to 79% without vascular disease (Figures 1A; P < 0.001). In a similar fashion, patients with diabetes had a 5-year survival rate of 47% vs. 63% without diabetes ( Figure 1B ; P = 0.03) and those in the highest quartile of the calcium phosphate product values had a survival rate of 48% vs. 61% for the rest (Figures 1B; P = 0.03). Factors including LVH, albumin, eGFR at the time of referral to the renal service, duration of follow-up serum cholesterol, triglycerides and smoking status at the time of first dialysis and the type of dialysis along with other co-morbidities like cancer were not significant in our analysis.
Discussion
This study has shown potential associations of several risk factors (lifestyle-related factors and co-morbidities) with mortality in dialysis patients in a single-centre RRT population. Analysis of the mortality data indicates that early mortality within the first year of commencing RRT accounts for more than half of the total mortality seen in our study population. Not surprisingly vascular disease and sepsis account for most of this mortality and can be accounted for by the nature of the risk factors for mortality identified from this analysis
The significance of calcium phosphate product and vascular disease burden at the commencement of dialysis on both early and overall mortality is striking. Although recognized in the literature as a risk factor, this study confirms its association with this particular Caucasian East Yorkshire population. As one may anticipate, diabetes and vascular disease were predictive of mortality over 5 years. The significance of elevated calcium phosphate product, late dialysis and increasing age, and low haemoglobin at the commencement of dialysis is intriguing.
From this analysis, we were able to identify various factors that affect (or associated with) early survival after initiation of dialysis in our patient Factors including time to dialysis from the point of referral, referral e-GFR, serum albumin, cholesterol, triglycerides, calcium phosphate product at first dialysis and history of various co-morbidities including CVA, ischaemic heart disease, cancer and COPD were not significant in the univariate analysis. population. Interestingly, age, low e-GFR at the start of first dialysis and low haemoglobin concentration had a significant impact on early mortality. The optimal timing of dialysis in patients with chronic renal failure still remains uncertain. There has been an overall trend towards earlier commencement of dialysis at higher eGFR values. Currently available data from some studies indicates that mortality while on dialysis therapy may be higher in those subjects with an early start. 7, 8 However, other investigators have argued that patients with chronic renal failure who begin dialysis at a relatively 'high level of residual renal function' (early start) may have lower morbidity and mortality compared with patients who begin dialysis at a more traditional 'low level of renal function' (late start). This hypothesis is based on evidence that declining renal function is associated with malnutrition and that malnutrition at the start of dialysis is associated with poor clinical outcomes. 9 Furthermore, patients are started on dialysis at an endogenous solute clearance that is lower than that accepted as optimum for patients on dialysis. Traditionally early start of dialysis has been defined as starting dialysis with an eGFR > 10 ml/min/ 1.73 m 2 . In our study population, both groups with and without early mortality had an eGFR < 10 ml/ min/1.73 m 2 (5.4 vs. 6.5 ml/min/1.73 m 2 , P = 0.06). Perhaps this may reflect the fact that a wait to commence dialysis until eGFR drops to around 5 ml/min/ 1.73 m 2 may adversely affect early survival. Another interesting finding from our results is the impact of haemoglobin on early mortality. Despite the controversy surrounding the optimal haemoglobin target in the dialysis population, several studies have shown increased mortality with low haemoglobin concentrations.
10,11 UK Renal Registry data from 2007 has shown that 58% of patients in the UK start dialysis with a haemoglobin of <10 g/dl. 12 In our study, 68% of patients started dialysis with a haemoglobin concentration <10 g/dl. Even though this did not have a significant effect on mortality for a longer term, early mortality was increased in patients with a haemoglobin <10.0 g/dl. This may possibly be due to anaemia management improving on dialysis as demonstrated from the registry data or simply reflect a potentially sicker population of patients prior to dialysis. It may also reflect the possibility of other interventions leading to protection against cardiac events.
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The prevalence of diabetes mellitus in the chronic kidney disease (CKD) population is increasing.
14 It represents both a strong cardiovascular risk factor and risk factor for mortality in both the general population and patients with end-stage renal disease (ESRD). 15, 16 Although coronary atherosclerosis is responsible for many of the cardiac events associated with diabetes, decreased coronary velocity reserve has been observed in diabetic patients with CKD. 17 Risk factors for cardiovascular disease remain sub-optimally managed in the diabetes population. 18 The European Dialysis and Transplant association registry data analysis has shown that young diabetics have a 10-fold higher coronary death rate as compared with their non-diabetic counterparts. 16 The combination of smoking and diabetes mellitus in patients with CKD in this study significantly increased the mortality risk when compared with non-smokers/non-diabetics. Previous studies have also shown that diabetic cigarette smokers have higher fibrinogen concentrations and higher systolic blood pressure values, a higher incidence of myocardial infarction and reduced 5-year survival when compared to non-smokers with diabetes. 19 Our data reiterate the importance of diabetes as an independent risk factor (association) for mortality over 5 years in the dialysis population. Therefore, early identification of diabetes and optimal management in a multidisciplinary fashion may help reduce associated complications that may increase mortality such as asymptomatic hypoglycaemia, autonomic dysfunction, microangiopathy and poor nutritional status.
Various studies have shown that higher death rates in patients with CKD reflect higher rates of atherosclerotic vascular disease. [3] [4] [5] [6] [20] [21] [22] Also, the number of risk factors for cardiovascular disease increases with the stage of CKD. 23 Our study has shown that the presence of cardiovascular disease during the pre-dialysis stage predicted mortality (both early and late) after the initiation of RRT (Figure 1 ). The Framingham heart study and other observational studies have shown that much of the aetiology of atherosclerotic cardiovascular disease is related to the presence of various modifiable risk factors. The various factors identified to be associated with mortality in this study are known to be predictive of vascular disease and vascular disease was the commonest cause of death in our study population. Together these facts stress the importance of prompt recognition and management of these risk factors at a very early stage of CKD.
Elevated serum phosphate is common in patients with CKD, occurring usually when the glomerular filtration rates falls below 30 ml/min. Dietary phosphate restriction and supplemental phosphate binders are beneficial in reducing serum levels. Hyperphosphataemia may lead to the development and progression of secondary hyperparathyroidism and a predisposition to metastatic calcification when the product of serum calcium and phosphorus (Ca þ 2 Â PO 2À 4 ) is elevated. Both of these conditions may contribute to the morbidity and mortality seen in patients with ESRD. [24] [25] [26] Laboratory and clinical studies have shown possible biological mechanisms to explain the relationship between bone mineral parameters and mortality. High serum phosphate levels can differentiate vascular smooth muscle cells into cells with osteoblastic activity, thereby promoting mineralization of the vascular system. 27, 28 Higher calcium intake is also associated with increased coronary calcification in young haemodialysis patients. 29 Raggi et al. 30 showed an association between higher serum calcium and phosphate levels and coronary calcification, in addition to a cross-sectional association of calcification with myocardial infarction (MI), angina and claudication. The results of our study have also suggested that elevated calcium phosphate product adversely affects mortality (Tables 3 and 4 ). This association exists even in the pre-dialysis stage (Tables 3 and 4) . Therefore, prompt active patient education, dietary intervention early and phosphate control without leading to hypercalcaemia would perhaps be a useful strategy to modifying this risk factor.
Conclusion
This study has demonstrated a significant mortality within the first year of commencing RRT in this cohort of patients. Elevated calcium phosphate product was identified as an important modifiable and lifestyle-driven risk factor of mortality after commencing dialysis. No randomized controlled studies have shown a significant beneficial effect of reduction of the calcium phosphate product on mortality. However, the recognized link with vascular calcification would suggest an association and therefore early intervention.
We have also demonstrated the importance of vascular disease burden at the start of dialysis on mortality. Factors such as increasing age, haemoglobin concentration and eGFR at the commencement of dialysis predicted early mortality. These observations suggest a tighter control of various risk factors for mortality at all stages of CKD perhaps by using a multidisciplinary approach to achieve it.
Limitations of the study
This study presents interesting findings but there are a number of limitations that should be acknowledged in consideration to the conclusions drawn. This is a relatively small single-centre study and as such makes methodological analysis of the multiple potential risk factors somewhat challenging. The study being observational only allows us to draw associations that will require validation in randomized controlled intervention studies. As the dataset in this series is not large, the multivariate analysis was not feasible. Therefore, a large prospective multicentre study to identify potential independent predictors of mortality at the time of entry onto the RRT programme with an aim to risk stratify the patients would be valuable to identify patients, especially in the elderly age group.
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